- Market Realist•14 hours ago
AstraZeneca is reducing its selling, general, and administrative expenses for better profitability. Its R&D costs will be in line with 2015.
- Market Realist•16 hours ago
AstraZeneca's (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.
- American City Business Journals•17 hours ago
Pharmaceutical giant AstraZeneca's agreement to sell much of its antibiotics business won't impact operations at MedImmune, its Gaithersburg-based research and development arm, officials confirmed Wednesday. MedImmune's infectious disease and vaccine portfolio for AstraZeneca (AZN) is focused exclusively on biologics, while AstraZeneca's deal with Pfizer Inc. — worth up to $1.6 billion — is specific to its small molecule antibiotics business .
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
|Bid||4,965.00 x 6100|
|Ask||5,180.00 x 13000|
|Day's Range||4,926.95 - 5,079.18|
|52wk Range||3,680.00 - 5,505.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||28.63|
|Avg Vol (3m)||2,806,334|
|Dividend & Yield||N/A (N/A)|